Theralase Technologies's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.00.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.01.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 13.80% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 9.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Theralase Technologies's EPS without NRI or its related term are showing as below:
TLTFF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.1 Med: 3.05 Max: 21.6
Current: 13.8
During the past 13 years, Theralase Technologies's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 21.60% per year. The lowest was -65.10% per year. And the median was 3.05% per year.
TLTFF's 3-Year EPS without NRI Growth Rate is ranked better than 57.74% of 665
companies
in the Medical Devices & Instruments industry
Industry Median: 8.2
vs TLTFF: 13.80
Theralase Technologies (OTCPK:TLTFF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Theralase Technologies EPS without NRI Related Terms
Theralase Technologies EPS without NRI Historical Data
* Premium members only.
The historical data trend for Theralase Technologies's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLTFF vs ABT, SYK, MDT: EPS without NRI Comparison
For the Medical Devices subindustry, Theralase Technologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's PE Ratio without NRI falls into.
Theralase Technologies EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a EPS without NRI of $-0.01 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Theralase Technologies and its competitors. According to the industry distribution chart, Theralase Technologies ranks #281 out of 665 companies in the Medical Devices & Instruments industry, placing it in the top 42.3%.
Is Theralase Technologies' EPS without NRI too high?
Theralase Technologies' current EPS without NRI is $-0.01. Based on the distribution chart, Theralase Technologies ranks #281 out of 665 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #281 out of 665 companies for EPS without NRI. This puts Theralase Technologies in the upper half of its industry. The industry median EPS without NRI is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.20, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current EPS without NRI is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.20 — trading 50.2% above its estimated fair value. The current EPS without NRI is $-0.01. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current EPS without NRI is $-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.20 is trading 50.2% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Significantly Overvalued.
Key valuation signals for TLTFF:
EPS without NRI: $-0.01
GF Value™: $0.13 vs. price of $0.20 (50.2% above fair value)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
